This Article Full Text (PDF) All Versions of this Article: 1756285609336399v1 2/5/319    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Ludolph, A. C. Articles by Jesse, S. Social Bookmarking                         What's this?

Review: Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany, albert.ludolph{at}rku.de

Sarah Jesse

Sarah Jesse Department of Neurology, University of Ulm, Germany

Amyotrophic lateral sclerosis/motor neuron disease is a severe neurodegenerative disease characterized by upper and lower motor neuron degeneration for which there is no truly effective treatment. Several therapies have shown promise in preclinical models of motor neuron disease; however, most of them failed in human studies, so that the noticeable progress in understanding the cellular mechanisms of motor neuron degeneration has not been matched with the development of therapeutic strategies to prevent disease progression or to extend survival longer than achieved by riluzole. We review treatment development in motor neuron disease and discuss the strengths and limitations of past as well as upcoming clinical trials.

Key Words: amyotrophic lateral sclerosis • evidence-based therapy • clinical trials

This version was published on September 1, 2009

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 5, 319-326 (2009)
DOI: 10.1177/1756285609336399


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?